Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study
Breier A, Buchanan RW, D'Souza D, Nuechterlein K, Marder S, Dunn W, Preskorn S, Macaluso M, Wurfel B, Maguire G, Kakar R, Highum D, Hoffmeyer D, Coskinas E, Litman R, Vohs JL, Radnovich A, Francis MM, Metzler E, Visco A, Mehdiyoun N, Yang Z, Zhang Y, Yolken RH, Dickerson FB. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Schizophrenia Research 2018, 206: 291-299. PMID: 30478008, DOI: 10.1016/j.schres.2018.11.002.Peer-Reviewed Original ResearchConceptsHSV-1Double-blind efficacy trialHerpes simplex virus 1 (HSV-1) infectionEarly phase schizophreniaSimplex virus 1 infectionVirus-1 infectionPathophysiology of schizophreniaPrimary endpointValacyclovir treatmentNegative subjectsRecent trialsVISTA studyEfficacy trialsLetter-Number Sequencing TestNegative groupPositive groupSevere formHerpes virusPositive symptomsMore impairmentTreatment resultsUS sitesCognitive deficitsNon-activated stateSchizophrenia39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY
Breier A, Dickerson F, Buchanan R, Marder S, Neuchterlein K, D’Souza D, Francis M, Radnovich A, Yolken R, Preskorn S, Macaluso M, Yang Z, Mehdyoun N, Kakar R, Dunn W, Hoffmeyer D, Maguire G. 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY. Schizophrenia Bulletin 2018, 44: s63-s63. PMCID: PMC5888721, DOI: 10.1093/schbul/sby014.162.Peer-Reviewed Original ResearchEarly phase schizophreniaHSV-1 seropositiveHSV-1Cognitive impairmentNegative subjectsHerpes virusPrevious small clinical trialsDuration of psychosisEfficacy of valacyclovirDouble-blind trialSmall clinical trialsHerpes virus infectionHerpes simplex virus type 1Treatment of schizophreniaSimplex virus type 1Life-long infectionVirus type 1Treatment outcome analysisMemory scoresFull therapeutic potentialPlacebo groupAdjunctive placeboInflammatory markersPrimary outcomeHuman CNS